6/23/2020 7:18:20 AM
ADMA Biologics Announces Martha Demski Elected To Board
2/6/2020 8:52:07 PM
ADMA Biologics Prices Underwritten Public Offering Of 23.50 Mln Shares At $3.50/shr
1/9/2020 7:11:32 AM
ADMA Biologics Q4 Preliminary Total Revenues $11.9 Mln, Up 193%
1/7/2020 7:09:20 AM
ADMA Biologics Enters Manufacturing And Supply Deal To Produce And Sell Plasma-Derived Intermediate Fractions
11/4/2019 7:10:14 AM
ADMA Biologics Announces Acceptance To The Plasma Protein Therapeutics Association
10/21/2019 8:17:44 AM
ADMA Biologics Announces First Commercial Sales Of ASCENIV
10/17/2019 7:40:42 AM
ADMA Biologics Announces Publication Of Article Describing Manufacturing Process Optimization For BIVIGAM And ASCENIV
8/22/2019 7:51:01 AM
ADMA Biologics Announces Commercial Relaunch And Its First Commercial Sales Of BIVIGAM
7/8/2019 8:33:54 AM
ADMA Biologics Receives FDA Approval For License Transfers For BIVIGAM And Nabi-HB
5/10/2019 7:10:57 AM
ADMA Biologics: FDA Approves Prior Approval Supplement For BIVIGAM; Says It Will Commence Commercial Sales Of BIVIGAM
4/4/2019 8:04:37 AM
WBB Securities Raises ADMA BIOLOGICS, INC. (ADMA) To Buy From Speculative Buy With $11.50 Price Target